Myelodysplastische Syndrome (MDS)

[1]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[2]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[3]  D. Steensma,et al.  Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Schlenk,et al.  Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.

[6]  C. Schumann,et al.  Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload , 2012, Annals of Hematology.

[7]  U. Germing,et al.  Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. , 2011, Leukemia research.

[8]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[9]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[10]  C. Schumann,et al.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Haferlach,et al.  Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia , 2011, British journal of haematology.

[12]  Luca Malcovati,et al.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome , 2011, Haematologica.

[13]  A. Ganser,et al.  Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Ganser,et al.  Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. , 2010, Leukemia research.

[15]  A. Stamatoullas,et al.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). , 2010, Leukemia research.

[16]  U. Germing,et al.  Incidence and Prevalence of Patients with Myelodysplastic Syndromes (MDS) in Düsseldorf 1996-2005. , 2009 .

[17]  D. Cella,et al.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.

[18]  U. Germing,et al.  The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome , 2009, Haematologica.

[19]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[20]  A. Ganser,et al.  Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes , 2008, Leukemia.

[21]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[22]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[23]  N. Gattermann,et al.  Valproic acid for the treatment of myeloid malignancies , 2007, Cancer.

[24]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[26]  C. Steidl,et al.  Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) , 2005, Leukemia.

[27]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Rimsza,et al.  Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.

[29]  U. Germing,et al.  Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.

[30]  John P Klein,et al.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.

[31]  Peter A. Jones,et al.  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.

[32]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Hagemeijer,et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.

[34]  P. Fenaux.  Chromosome and Molecular Abnormalities in Myelodysplastic Syndromes , 2001, International journal of hematology.

[35]  U. Germing,et al.  Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.

[36]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[37]  P. Venugopal,et al.  Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. , 2000, Blood.

[38]  H. Deeg,et al.  Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. , 2000, Blood.

[39]  P. Greenberg,et al.  Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.

[40]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[41]  H. Gralnick,et al.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group , 1994, British journal of haematology.

[42]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.

[43]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.